Posts

Electra Targets Nearly $300M IPO

on

GSK seeks to expand Nuvalent lung cancer drug use with new positive data

on

GSK strikes up to $750 million deal for Chimagen blood-cancer therapy

on

LBL-024 Shows Promising Early Results in First-Line NSCLC

on

Scholar Rock wins FDA approval for ISEMBYLD SMA therapy after year-long manufacturing delay

on

AstraZeneca’s Camizestrant Misses Key First-Line Breast-Cancer Trial Goal

on

Definium reports another Phase 3 win for LSD-based anxiety drug DT120

on

Scholar Rock wins FDA approval for ISEMBYLD, a muscle-targeted SMA treatment

on

Novo Nordisk seeks a reset after major setbacks

on

FDA Reassesses Rare-Disease Trial Standards and Endpoint Selection

on

GSK to wind down Dresden vaccine factory amid weak flu-vaccine demand

on

Ivonescimab Shows Survival Advantage Over Keytruda in Lung Cancer Trial

on

Cyclic peptides advance toward new drug targets, but manufacturing capacity may determine how fast

on

Allarity Therapeutics Files Registration Statement for Proposed $100 Million SPAC IPO

on

GSK’s Ris-Rez cuts death risk by 54% in relapsed small-cell lung cancer trial

on

Novartis board faces investor scrutiny after M&A misfires and R&D setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Novartis’s Triple Clinical Setback Hits Shares and Weighs on Pharma Peers

on

FDA delays decision on Exelixis colorectal-cancer drug to March 2027

on